Metabolism of ethylbenzene by human liver microsomes and recombinant human cytochrome P450s (CYP)
Introduction
Ethylbenzene is a commonly used chemical with several industrial applications. It is a solvent (often mixed with other aromatic solvents such as xylene and toluene), an intermediate in the synthesis of styrene, a raw material for the production of rubber and plastics, and an additive to some fuels (Cavender, 1994, WHO, 1996). The absorption of ethylbenzene in exposed workers arises mainly via inhalation, and to a much lesser extent through the dermal route (Gromiec and Piotrowski, 1984, Fishbein, 1985). Ethylbenzene has low acute and chronic toxicity, but it acts as a central nervous system depressant at high doses and can cause mild irritation of the mucous membranes and eyes (WHO, 1996). Therefore, it is important to control and minimise worker exposure to ethylbenzene. Its metabolites can be detected in urine, and the major product, mandelic acid, is recommended for biological monitoring of ethylbenzene (ACGIH, 2000).
Human in vivo studies have shown that mandelic acid and phenylglyoxylic acid are the major urinary metabolites following inhalation exposure to ethylbenzene (Bardodej and Bardodejova, 1970, Engstrom et al., 1984). These metabolites result from initial hydroxylation of the side chain of ethylbenzene, followed by further oxidation. Some minor ring oxidation metabolites have also been detected in urine, but these account for less than 5% of total metabolites (Engstrom et al., 1984).
Knowledge of the toxicokinetics of a chemical and the individual enzymes involved in its metabolism can improve interpretation of biological monitoring results and risk assessment by predicting the range of biotransformation rates that might be expected in the general population. In vitro metabolic systems, such as liver microsomes, have been extensively employed to study rates of biotransformation and data can be scaled to predict in vivo clearances (Houston, 1994, MacGregor et al., 2001). As part of ongoing studies of industrial solvents, the In vitro metabolism of ethylbenzene has been investigated in human liver microsomes obtained from individual donors. The aims of this study were to determine the kinetic parameters for the initial oxidation of ethylbenzene to 1-phenylethanol and to characterise the forms of cytochrome P450 (CYP) involved in this reaction.
Section snippets
Chemicals
Ethylbenzene and its metabolite, 1-phenylethanol, were obtained from Sigma–Aldrich (Gillingham, UK). All other chemicals used were of analytical grade or better.
Human liver microsomes and recombinant human cytochrome P450 isoforms
Human liver microsomes were obtained from TCS Cellworks (Botolph Claydon, UK; distributors for BioPredic, Rennes, France). Collection and processing of human tissue was conducted in compliance with all current regulatory and ethical requirements. Microsomes were characterised for activity towards a range of model CYP substrates. Donor
Analytical and experimental precision
The limit of detection for 1-phenylethanol was 50 pmol (0.5 μM). At 500 pmol (5 μM), the coefficient of variation of the assay was 4.5% within batch (n=6) and 14% between batches (n=14). Experimental precision for duplicate microsomal incubations from separate experiments analysed independently was 7% at 1 mM (n=3) and 20% at 50 μM ethylbenzene (n=5).
Ethylbenzene metabolism by human liver microsomes
The microsomal protein concentration and incubation time used in this study were both within linear ranges determined in preliminary experiments. No
Discussion
We present human liver microsomal data for the initial step of ethylbenzene metabolism, namely side chain oxidation to form 1-phenylethanol. Our findings suggest strongly that, like many other low molecular weight chemicals, ethylbenzene is predominantly metabolised by CYP2E1 (Guengerich et al., 1991). However, in common with other structurally related compounds including xylene and toluene, ethylbenzene metabolism exhibited biphasic kinetics characterised by a high- and a low-affinity
Acknowledgements
This work was funded by the UK Health and Safety Executive.
References (29)
The integration of data on physico-chemical properties, in vitro-derived toxicity data and physiologically based kinetic and dynamic as modelling a tool in hazard and risk assessment. A commentary
Toxicol. Lett.
(2003)An overview of environmental and toxicological aspects of aromatic hydrocarbons IV
Ethylbenzene. Sci. Tot. Environ.
(1985)- et al.
Chlormethiazole inhibition of cytochrome P450 2E1 as assessed by chlorzoxazone hydroxylation in humans
Hepatology
(1997) - et al.
The use of in vitro metabolic parameters and physiologically based pharmacokinetic (PBPK) modeling to explore the risk assessment of trichloroethylene
Environ. Toxicol. Pharm.
(2002) - et al.
Inducibility of human cytochromes P-450 primarily involved in the activation of chemical carcinogens
Chemosphere
(1992) - et al.
Incorporating human interindividual biotransformation variance in health risk assessment
Sci. Tot. Environ.
(2002) - ACGIH, 2000. Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices,...
- et al.
Biotransformation of ethylbenzene, styrene and alpha-methylstyrene in man
Am. Ind. Hyg. Assoc. J.
(1970) - et al.
Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA expressed human cytochromes P-450
Drug Metab. Dispos.
(1999) - Cavender, F., 1994. Ethylbenzene. In: Claydon, G., Claydon, F. (Eds.), Patty’s Industrial Hygiene and Toxicology....